Close

Gilead Sciences (GILD) Announces Kite's Yescarta Becomes First CAR T Therapy Approved by FDA for Treatment of Adult Patients With R/R Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy

October 18, 2017 5:46 PM EDT Send to a Friend
Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login